key: cord-0788127-c6aelkbj
authors: Ismail, Ismail Ibrahim; Al-Hashel, Jasem; Alroughani, Raed; Ahmed, Samar Farouk
title: A case report of multiple sclerosis after COVID-19 infection: causality or coincidence?
date: 2021-08-10
journal: Neuroimmunology Reports
DOI: 10.1016/j.nerep.2021.100008
sha: 317de19228612466d56ece4821b0ac07463af991
doc_id: 788127
cord_uid: c6aelkbj

Introduction Since the declaration of COVID-19 pandemic, several cases of demyelination of both peripheral and central nervous systems have been reported. The association of viral infection and the development of CNS demyelination has long been studied, and this link has recently been reported following SARS-CoV-2 infection as well. Case report We report a case of a 36-year-old male who developed CNS demyelinating disease, that fulfilled the diagnostic criteria of multiple sclerosis (MS), 2 months after laboratory-confirmed infection with SARS-CoV-2. Conclusion To our knowledge, this is the second published case report of MS in association with COVID-19 infection, and the first case from Middle East and North Africa (MENA) region, adding to the growing literature of a probable causal relationship between SARS‐CoV‐2 infection and the development of MS.

Since the declaration of coronavirus disease 2019 (COVID-19) pandemic in March 2020, it has become increasingly evident that several neurological complications can occur in association with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. It has been estimated that more than one-third of patients with COVID-19 developed neurological complications during the acute phase, and more than one-third developed neuropsychiatric complications 6 months after infection (1) .

In the setting of severe COVID-19 infection, a combination of systemic inflammation, hypercoagulability, and neuroinflammation may result in central nervous system (CNS) damage. As regards to demyelinating diseases, several cases of both central and peripheral nervous systems demyelination have been reported following COVID-19 infection. Viral infection has long been linked to the development of CNS demyelination, and this association has been reported following SARS-CoV-2 infection as well (2) .

Herein, we report a case of a 36-year-old male who presented with CNS demyelinating disease, that fulfilled the diagnostic criteria of multiple sclerosis (MS), 2 months after a laboratory-confirmed infection with SARS-CoV-2.

A 36-year-old right handed male, with history of idiopathic generalized epilepsy since the age of 10 years, presented to our neurology outpatient clinic with unsteady gait and sense of imbalance of a one-month duration in March 2021. His epilepsy was well-controlled, and he was maintained on levetiracetam 1 gm per day. His latest magnetic resonance imaging (MRI) was in January 2020, and was normal (Figure 1) . In December 2020, he developed fever, cough, generalized body pain, and he tested positive for SARS-CoV-2 via a nasopharyngeal swab reverse transcription-polymerase chain reaction (RT-PCR). He had an uncomplicated course of illness, and was managed conservatively at home. In February 2021, he started to have gait instability, recurrent falls, incoordination and dizziness, in the absence of any other cognitive, bulbar, sensory, motor or sphincteric complaint. On examination, he was alert, conscious, and oriented with normal speech and higher mental functions. He had unsteady gait with inability for tandem walking. Cranial nerves assessment was normal, apart from 

We report a case of CNS demyelination following SARS-CoV-2 infection, that fulfilled the Several experimental studies revealed that murine coronavirus infection of susceptible mice has led to an inflammatory demyelination similar to MS, with coronavirus RNA sequences and its antigen detected in demyelinating lesions (5) . Several recent studies investigated the possible mechanisms of COVID-19 associated neurological complications. SARS-CoV-2 exhibits neurotropic properties and can cause direct neurological damage, through binding to angiotensin-converting enzyme-2 (ACE-2) receptors in CNS, or via blood circulation. Moreover, delayed CNS damage appears to be mediated by an undesired immune reaction, leading to acute or delayed CNS demyelination (6) . Accumulated evidence showed that SARS-CoV-2 and several proinflammatory cytokines, including IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α, and IFN-γ, can cross the bloodbrain-barrier, infecting macrophages, microglia, and astrocytes, which are the principal cells that mediate innate immunity in the CNS, thus creating a "perfect storm" for a proinflammatory state (7) . IL-6 is an important pro-inflammatory mediator that can induce an immune response in the nervous system, and plays a crucial role in regulating the immune response in MS. In EAE model of MS, IL-6 aggravates clinical manifestations, neuroinflammation, and demyelination, principally by promoting pathogenic T helper-17 cell generation in the peripheral lymphoid organs (7) . The levels of IL-6 were found to be correlated with the severity of COVID-19 symptoms, and this dysregulation can affect both innate and acquired immunity. Furthermore, most COVID-19 patients exhibit increased circulating levels of IL-17, which has a documented role in MS pathogenesis, based on the data from EAE model (8) .

In addition, Toll-like receptors (TLR), the main pattern recognition receptors in CNS, have played a significant role in the pathogenesis of both MS and COVID-19, mainly through recognition of viral particles, activation of the innate immune-system, and secretion of proinflammatory cytokines (9) .

A possible alternative explanation could be the production of antibodies against myelin triggered by the virus. This para-infectious or post-infectious etiology is reported in several cases of post-SARS-CoV-2 Guillain-Barre syndrome. SARS-CoV-2 may play a role in triggering MS, similar to the documented role of EBV (10).

We report a case of CNS demyelination following COVID-19 infection, that fulfilled the diagnostic criteria of MS. Our case adds to the growing field of research on the influence of SARS-CoV-2 on the nervous system, potentially triggering demyelination through an autoimmune CNS inflammatory process. Clinical and radiological monitoring is recommended in such cases, as the course of the demyelinating disease still seems unpredictable.

6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. The Lancet Psychiatry

Could SARS-CoV-2 herald a surge of multiple sclerosis?

A first presentation of multiple sclerosis with concurrent COVID-19 infection. Eneurologicalsci

Coronaviruses and neuroantigens: myelin proteins, myelin genes

Nervous system involvement after infection with COVID-19 and other coronaviruses

Unraveling the possible routes of SARS-COV-2 invasion into the central nervous system

Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors

The role of interleukin-6 in central nervous system demyelination

Role of Toll-like receptors in the pathogenesis of COVID-19

Guillain-Barre Syndrome following COVID-19 Infection: First Case Report from Kuwait and Review of the Literature

The authors declare that they have no conflict of interest.

Approval was obtained from the Scientific Research Committee of Department of Neurology at Ibn Sina Hospital.

Informed consent was obtained from the patient.

Ismail Ibrahim Ismail https://orcid.org/0000-0002-9788-7044

III, and SFA were involved with acquisition of data. III, RA, JYA and SFA treated the patient. III, and SFA wrote the initial manuscript. III performed the literature review. All authors critically appraised and revised it. All authors read and approved the final manuscript.

No specific funding reported for this study.

All data related to this case report are available on request to the corresponding author